MARKSANS · NSE
Marksans Pharma Limited
₹320.15
+0.14% (+₹0.45)
Prev. close
₹319.7
Volume
9,75,318
Delivery %
49.0%
As of
18 Sept 2026
Price history
Vaishali Parekh · Prabhudas Lilladher · 27 Aug 2026
“Recommends buying Marksans Pharma at ₹332, targeting ₹350, with a stop loss at ₹320.”
Entry ₹332Target ₹350 (+5.4%)Stop ₹320 (-3.6%)R:R 1.5:1Stopped out · 31 Aug 2026
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
1 · 1 bull / 0 neutral / 0 bear
Long-Horizon
none in window
Commentary
none in window
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Recommends buying Marksans Pharma at ₹332, targeting ₹350, with a stop loss at ₹320.” | Vaishali ParekhPrabhudas Lilladher | Marksans Pharma | PENDING | ||||
“Recommends buying Marksans Pharma at ₹332, targeting ₹350, with a stop loss at ₹320.” This call hasn't reached its evaluation window yet — the verdict will appear here once it's graded. | |||||||
Fundamentals
About Marksans Pharma Limited
Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Mark B. Saldanha
Headquarters
Mumbai
Employees
1,685
Website
marksanspharma.comExchange
View on NSE ↗Key stats
Market cap
₹14,508.04 Cr
P/E ratio (TTM)
28.1
Dividend yield
0.28%
EPS (TTM)
₹11.41
Beta (1Y · daily vs NIFTY 50)
1.07
Beta (5Y · monthly vs NIFTY 50)
1.80
Shares float
21.44 Cr
EPS · quarter ended Jun 2026
₹3.47
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,376.18 Cr | ₹1,490.84 Cr | ₹1,852.14 Cr | ₹2,177.41 Cr | ₹2,614.45 Cr | ₹2,950.94 Cr | |
| EBITDA | ₹346.30 Cr | ₹300.73 Cr | ₹398.63 Cr | ₹509.00 Cr | ₹599.01 Cr | ₹683.31 Cr |
| ₹236.00 Cr | ₹185.00 Cr | ₹266.31 Cr | ₹313.70 Cr | ₹380.58 Cr | ₹417.90 Cr | |
| Diluted EPS | ₹5.76 | ₹4.51 | ₹6.41 | ₹6.92 | ₹8.4 | ₹9.22 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,228.00 Cr | ₹1,636.00 Cr | ₹2,190.00 Cr | ₹2,681.00 Cr | ₹3,240.00 Cr | ₹3,856.00 Cr | |
| — | ₹110.78 Cr | ₹122.95 Cr | ₹244.06 Cr | ₹321.91 Cr | ₹343.38 Cr | |
| Stockholders' equity | ₹887.00 Cr | ₹1,202.00 Cr | ₹1,745.00 Cr | ₹2,065.00 Cr | ₹2,467.00 Cr | ₹3,023.00 Cr |
Cash & equivalents, Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹179.00 Cr | ₹99.00 Cr | ₹237.00 Cr | ₹230.00 Cr | ₹207.00 Cr | ₹458.00 Cr | |
| Investing cash flow | ₹-44.90 Cr | ₹-41.69 Cr | ₹-259.21 Cr | ₹-140.84 Cr | ₹-49.01 Cr | ₹-248.27 Cr |
| ₹-15.29 Cr | ₹79.51 Cr | ₹197.83 Cr | ₹-68.73 Cr | ₹-65.15 Cr | ₹-70.93 Cr | |
| Capital expenditure | ₹-46.42 Cr | ₹-46.33 Cr | ₹-53.63 Cr | ₹-208.84 Cr | ₹-172.92 Cr | ₹-130.53 Cr |
| End cash position | ₹212.29 Cr | — | ₹382.44 Cr | ₹403.28 Cr | ₹495.79 Cr | ₹634.14 Cr |
Debt issued, Debt repaid, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 22(4Q) | Sep 22 | Dec 22 | Jan 23 | Mar 23–Mar 24(5Q) | Jun 24–Jun 26(9Q) |
|---|---|---|---|---|---|---|
| Promoter | 48.25% | 48.60% | 49.00% | 43.80% | 43.85% | 43.87% |
| Public | 51.75% | 51.40% | 51.00% | 56.20% | 56.15% | 56.13% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Marksans Pharma Limited | ₹14,487.65 Cr | ₹320.15 | 28.1 | 4.79 | 13.8% | 0.11 | +12.5% | +79.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 22
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
10 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Marksans Pharma (NSE:MARKSANS): What Is the SEBI Special Window for Physical Share Transfers?
Kalkine India · 2 days ago
Marksans Pharma: Shareholders Approve Dividend and Director Re-appointments at AGM
Marksans Pharma shareholders approved all resolutions at their 34th Annual General Meeting. This includes the declaration of a final dividend of ₹0.90 per share and the re-appointment of directors. The approvals reflect strong shareholder confidence in the company's governance and financial performance.